Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Metastatic Progression of Human Melanoma: 2nd Edition
share announcement

Metastatic Progression of Human Melanoma: 2nd Edition

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 25 September 2025 | Viewed by 465

Special Issue Editors

Prof. Dr. Jozsef Timar

E-Mail Website
Guest Editor
2nd Department of Pathology, Semmelweis University, Budapest, Hungary
Interests: melanoma; progression; genomics; signaling
Special Issues, Collections and Topics in MDPI journals
Dr. Andrea Ladányi

E-Mail Website
Guest Editor
Országos Onkológiai Intézet Budapest, Budapest, Hungary
Interests: melanoma; immune microenvironment; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of “Metastatic Progression of Human Melanoma”, available at https://www.mdpi.com/journal/cancers/special_issues/MPOHM.

Melanoma is the most metastatic human cancer and can progress even from a very small sub-millimeter-sized primary. Accordingly, to understand the biology behind it may not only reveal the unique molecular determinants of this biology, but may also identify the common, pan-cancer characteristics of metastatic progression. This Special Issue of Cancers is dedicated to human melanoma progression. Although there were fundamental improvements in the management of the metastatic disease of melanoma patients, the disease itself is still not curable when it becomes metastatic. To further improve the treatment of melanoma, we have to better understand the biology, the genetic background behind, the unique immunology of melanoma, and, most importantly, the background of therapy resistance, whether chemo-, targeted, or immunological. We expect submissions for this endeavor from researchers, molecular pathologists, immunologists, and oncologists who can contribute to a better understanding of melanoma.

Prof. Dr. Jozsef Timar
Dr. Andrea Ladányi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • human melanoma
  • metastasis models
  • oncogenic signaling
  • organ metastasis
  • genomics
  • immune microenvironment
  • prognosticators
  • predictors of target therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

19 pages, 324 KiB  
Review
Clinical Applications of the Molecular Landscape of Melanoma: Integration of Research into Diagnostic and Therapeutic Strategies
by Imre Lőrinc Szabó, Gabriella Emri, Andrea Ladányi and József Tímár
Cancers 2025, 17(9), 1422; https://doi.org/10.3390/cancers17091422 - 24 Apr 2025
Viewed by 320
Abstract
The molecular landscape of cutaneous melanoma is complex and heterogeneous, and a deeper understanding of the genesis and progression of the tumor driven by genetic alterations is essential for the development of effective diagnostic and therapeutic strategies. Molecular diagnostics and the use of [...] Read more.
The molecular landscape of cutaneous melanoma is complex and heterogeneous, and a deeper understanding of the genesis and progression of the tumor driven by genetic alterations is essential for the development of effective diagnostic and therapeutic strategies. Molecular diagnostics and the use of biomarkers are increasingly playing a role in treatment decisions. However, further research is urgently needed to elucidate the relationships between complex genetic alterations and the effectiveness of target therapies (although BRAF mutation is still the only targeted genetic alteration). Further research is required to exploit other targetable genetic alterations such as NRAS, KIT or rare mutations. Treatment guidelines for cutaneous melanoma are continually evolving based on data from recent and ongoing clinical trials. These advancements reflect changes mainly in the optimal timing of systemic therapy and the choice of combination therapies increasingly tailored to molecular profiles of individual tumors. Mono- or combination immunotherapies demonstrated unprecedented success of melanoma treatment; still, there is room for improvement: though several factors of primary or acquired resistance are known, they are not part of patient management as biomarkers. The novel developments of cancer vaccines to treat melanoma (melanoma-marker-based or personalized neoantigen-based) are encouraging; introduction of them into clinical practice without proper biomarkers would be the same mistake made in the case of first-generation immunotherapies. Full article
(This article belongs to the Special Issue Metastatic Progression of Human Melanoma: 2nd Edition)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop